ARRIVENT BIOPHARMA, INC.

Highlights ArriVent BioPharma, Inc.

Equities

AVBP

US04272N1028

Market Closed - Nasdaq Other stock markets 01:30:00 15/06/2024 am IST			5-day change	1st Jan Change
18.7 ^USD	-0.69%		+0.81%	0.00%

05/06	ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	MT
05/06	Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	05/06	MT
Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	05/06	MT
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Enters into Research and Collaboration Agreement with Arrivent Biopharma, Inc	05/06	CI
ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
ArriVent BioPharma, Inc. has completed an IPO in the amount of $174.999996 million.	25/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer